BioWorld Asia

Aug. 24, 2005

Biovitrum Acquires Arexis, Enters Deal With Santhera

Biovitrum AB completed its second acquisition of the year, agreeing to a cash and share takeover of fellow Swedish firm Arexis AB. (BioWorld International) Read More

Cerenis Brings In $30.5M For HDL-Enhancing Drugs

Search-And-Destroy Cancer Products Fulfilling Promise

Bavarian Nordic, Acambis Jocky For MVA Contract

U.S. Firm Amphion Capital Goes Public With £5M Listing On AIM

Oncodesign Developing Novel Cancer Treatments

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...